Trial Profile
Efficacy and tolerability of tariquidar in patients with doxorubicin or taxane resistant advanced breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tariquidar (Primary) ; Antineoplastics
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors QLT
- 05 Nov 2010 New trial record.